US Patent Issued to Arvinas Operations on March 31 for "Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (LRRK2)" (Pennsylvania, Connecticut Inventors)

ALEXANDRIA, Va., March 31 -- United States Patent no. 12,589,156, issued on March 31, was assigned to Arvinas Operations Inc. (New Haven, Conn.).

"Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (LRRK2)" was invented by Steven M. Sparks (Guilford, Conn.) and Michael Berlin (Yardley, Pa.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are compounds (e.g., compounds of Formula (Ia)) that function to recruit LRRK2 protein or a mutated version thereof to an E3 ubiquitin ligase for targeted ubiquitination and subsequent proteasomal degradation."

The patent was filed on March 24, 2025, under Application No. 19/088,147.

*For furt...